Related Experiment Videos

Induction by adozelesin and hydroxyurea of origin recognition complex-dependent DNA damage and DNA replication

M Weinberger1, P A Trabold, M Lu

  • 1Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

Insights

DNA damaging agents trigger a cell cycle checkpoint that halts DNA replication. This study reveals how adozelesin affects this process in yeast, identifying key genetic factors involved in DNA replication and damage response.

Area of Science:

  • Molecular Biology
  • Cell Cycle Regulation
  • DNA Damage Response

Background:

  • DNA damaging agents activate conserved intra-S-phase checkpoints in eukaryotic cells, inhibiting DNA replication.
  • Understanding these checkpoints is crucial for evaluating the efficacy of DNA-damaging antitumor drugs.

Purpose of the Study:

  • To investigate the effects of the DNA-alkylating agent adozelesin on Saccharomyces cerevisiae chromosome replication.
  • To elucidate the role of the origin recognition complex (ORC) in the intra-S-phase DNA damage checkpoint.

Main Methods:

  • Treatment of Saccharomyces cerevisiae with adozelesin and hydroxyurea.
  • Analysis of DNA replication initiation in wild-type and orc2-1 mutant cells.
  • Genetic manipulation including gene deletion (SAS2) and temperature-sensitive mutations.

Main Results:

  • Adozelesin inhibited DNA replication initiation in S. cerevisiae by inducing an intra-S-phase DNA damage checkpoint.
  • The inhibitory effect of adozelesin was abolished in orc2-1 cells, which have defects in initiation and checkpoint regulation.
  • Deletion of SAS2 suppressed initiation and checkpoint defects in the orc2-1 strain.
  • Adozelesin induced a G(1)-specific response dependent on ORC function.

Conclusions:

  • The origin recognition complex (ORC) plays a critical role in the intra-S-phase DNA damage checkpoint response to adozelesin.
  • SAS2 gene deletion can rescue defects in DNA replication initiation and checkpoint control.
  • A conserved G(1)-specific response involving ORC may contribute to the antitumor activity of DNA-damaging drugs in mammals.

Related Concept Videos